This AOP is licensed under the BY-SA license. This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
AOP: 114
Title
HPPD inhibition leading to corneal papillomas and carcinomas (in rat)
Short name
Graphical Representation
Point of Contact
Contributors
- Charles Wood
Coaches
OECD Information Table
OECD Project # | OECD Status | Reviewer's Reports | Journal-format Article | OECD iLibrary Published Version |
---|---|---|---|---|
1.29 |
This AOP was last modified on April 29, 2023 16:02
Revision dates for related pages
Page | Revision Date/Time |
---|---|
Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme | December 03, 2016 16:37 |
Increased, Plasma tyrosine | September 16, 2017 10:16 |
Increase, Cytotoxicity (corneal cells) | September 16, 2017 10:16 |
Increase, Inflammation (corneal cells) | September 16, 2017 10:16 |
Increase, Regenerative cell proliferation (corneal cells) | September 16, 2017 10:16 |
Increase, Papillomas/carcinomas (squamous cells) | September 16, 2017 10:16 |
Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme leads to Increased, Plasma tyrosine | December 03, 2016 16:38 |
Increased, Plasma tyrosine leads to Increase, Cytotoxicity (corneal cells) | December 03, 2016 16:38 |
Increase, Cytotoxicity (corneal cells) leads to Increase, Inflammation (corneal cells) | December 03, 2016 16:38 |
Increase, Inflammation (corneal cells) leads to Increase, Regenerative cell proliferation (corneal cells) | December 03, 2016 16:38 |
Increase, Regenerative cell proliferation (corneal cells) leads to Increase, Papillomas/carcinomas (squamous cells) | December 03, 2016 16:38 |
Abstract
This putative adverse outcome pathway (AOP) outlines potential key events leading to a tumor outcome in standard carcinogenicity models. This information is based largely on modes of action described previously in cited literature sources and is intended as a resource template for AOP development and data organization. Presentation in this Wiki does not indicate EPA acceptance of a particular pathway for a given reference agent, only that the information has been proposed in some manner. In addition, this putative AOP relates to the model species indicated and does not directly address issues of human relevance.
AOP Development Strategy
Context
Strategy
Summary of the AOP
Events:
Molecular Initiating Events (MIE)
Key Events (KE)
Adverse Outcomes (AO)
Type | Event ID | Title | Short name |
---|
MIE | 766 | Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme | Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme |
KE | 775 | Increased, Plasma tyrosine | Increased, Plasma tyrosine |
KE | 776 | Increase, Cytotoxicity (corneal cells) | Increase, Cytotoxicity (corneal cells) |
KE | 777 | Increase, Inflammation (corneal cells) | Increase, Inflammation (corneal cells) |
KE | 778 | Increase, Regenerative cell proliferation (corneal cells) | Increase, Regenerative cell proliferation (corneal cells) |
AO | 779 | Increase, Papillomas/carcinomas (squamous cells) | Increase, Papillomas/carcinomas (squamous cells) |
Relationships Between Two Key Events (Including MIEs and AOs)
Title | Adjacency | Evidence | Quantitative Understanding |
---|
Network View
Prototypical Stressors
Life Stage Applicability
Taxonomic Applicability
Term | Scientific Term | Evidence | Link |
---|---|---|---|
Rattus norvegicus | Rattus norvegicus | NCBI |
Sex Applicability
Sex | Evidence |
---|---|
Male | |
Female |
Overall Assessment of the AOP
Domain of Applicability
Essentiality of the Key Events
Evidence Assessment
Known Modulating Factors
Quantitative Understanding
Considerations for Potential Applications of the AOP (optional)
References
Lewis, R. W., & Botham, J. W. (2013). A review of the mode of toxicity and relevance to humans of the triketone herbicide 2-(4-methylsulfonyl-2-nitrobenzoyl)-1,3-cyclohexanedione. Crit Rev Toxicol, 43(3), 185-199. doi: 10.3109/10408444.2013.764279
U.S. Environmental Protection Agency. (September 7, 2007). Tembotrione Human Health Risk Assessment.: Retrieved from http://www.regulations.gov/.